Evidence map›Paper›PMID 41234881›Full record

ArticleTranslational cancer research2025

Xinglin Zhang, Peirong Li, Hongbo Zhao

Abstract read
In one paragraph

Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xinglin ZhangThe First Clinical Medical College, Kunming Medical University, Kunming, China.
Peirong LiDepartment of Laboratory Animal Science, Kunming Medical University, Kunming, China.
Hongbo ZhaoDepartment of Laboratory Animal Science, Kunming Medical University, Kunming, China.ORCID https://orcid.org/0000-0002-8498-5577

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: CCT4 is a key molecular chaperone and its dysfunction may impair actin or microtubule assembly, potentially driving hepatocellular carcinoma (HCC) progression. However, its roles in multiple cell types and tumor microenvironment infiltration in HCC remain unclear. This study aimed to investigate the biological functions of Methods: Results: Conclusions:

Indexed as

CCT4Hepatocellular carcinoma (HCC)immune infiltrationprognosissingle-cell RNA sequencing (scRNA-seq)

Identifiers

PMID41234881
PMCPMC12605557

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.